BOLT BIOTHERAPEUTICS
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates.
BOLT BIOTHERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.boltbio.com
Total Employee:
11+
Status:
Active
Contact:
(310)909-3218
Email Addresses:
[email protected]
Total Funding:
198.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Genmab
Genmab investment in Post-IPO Equity - Bolt Biotherapeutics
Samsara BioCapital
Samsara BioCapital investment in Series C - Bolt Biotherapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Bolt Biotherapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - Bolt Biotherapeutics
Vivo Capital
Vivo Capital investment in Series C - Bolt Biotherapeutics
Surveyor Capital
Surveyor Capital investment in Series C - Bolt Biotherapeutics
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series C - Bolt Biotherapeutics
Novo Holdings
Novo Holdings investment in Series C - Bolt Biotherapeutics
RA Capital Management
RA Capital Management investment in Series C - Bolt Biotherapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - Bolt Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-09 | Bolt Bio Adds Mayo Clinic’s Edith Perez as Chief Medical Officer |
Official Site Inspections
http://www.boltbio.com Semrush global rank: 3.58 M Semrush visits lastest month: 4.04 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Bolt Biotherapeutics"
Bolt Biotherapeutics - Finding better ways …
At Bolt, we are leveraging the immune system for a better way to treat cancer. Our approach works with a person’s body, not against it. We do this by using the innate immune system, …See details»
Bolt Biotherapeutics - Crunchbase Company Profile & Funding
Organization. Bolt Biotherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; …See details»
Bolt Biotherapeutics, Inc. (BOLT) Company Profile & Facts - Yahoo …
See the company profile for Bolt Biotherapeutics, Inc. (BOLT) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Governance Highlights - Bolt Biotherapeutics
The Board of Directors of Bolt Biotherapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»
Bolt Biotherapeutics, Inc. - LinkedIn
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of ...See details»
Bolt Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
For additional information, please contact Bolt Biotherapeutics at 1-650-665-9295 or [email protected]. References 1. S. ... The statistics for drugs in the Pipeline is the current …See details»
Bolt Biotherapeutics (BOLT) Company Profile & Description - Stock …
Feb 5, 2021 Company profile for Bolt Biotherapeutics, Inc. (BOLT) stock, with a description, list of executives, contact details and other key facts.See details»
Bolt Biotherapeutics - Craft
Oct 29, 2024 Bolt Biotherapeutics has 4 employees at their 1 location and $7.88 m in annual revenue in FY 2023. See insights on Bolt Biotherapeutics including office locations, …See details»
Orphanet: BOLT BIOTHERAPEUTICS
E-mail: [email protected]. Phone 1: 1 (650) 665-9295 Bolt Biotherapeutics Bolt Biotherapeutics 900 Chesapeake Drive 94063 REDWOOD CITY, CA 94063 CA UNITED STATES. Phone 1: 1 …See details»
Pipeline - Bolt Biotherapeutics
BDC-4182. BDC-4182 is a next-generation Boltbody TM ISAC targeting claudin 18.2, a clinically validated target with expression in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and other tumor types. …See details»
Bolt Biotherapeutics - workinbiotech.com
Bolt Biotherapeutics is developing immuno-oncology therapies to eliminate tumors. Many tumors create an immune-suppressive environment to prevent their clearance. Bolt is leveraging the …See details»
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer ...
-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their …See details»
Bolt Therapeutics (USA) Funding: $198.5M
Feb 26, 2025 Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer...See details»
Bolt Biotherapeutics Inc - Company Profile - GlobalData
Year Event Description; 2021: Contracts/Agreements: In September, the company and Bristol-Myers Squibb entered into a clinical collaboration and supply agreement to investigate Bolt …See details»
Bolt Biotherapeutics Announces Changes to its Board of Directors
Sep 4, 2024 These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov. Investor Relations …See details»
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 ...
5 days ago BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025; BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting …See details»
Bolt Biotherapeutics Appoints William P. Quinn as Chief Financial …
Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com. Media Contacts: Maggie Beller or David Schull Russo Partners, LLC 646 …See details»
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year
4 days ago These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov. Investor Relations …See details»
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 ...
Dec 31, 2024 BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting …See details»
Our Science - Bolt Biotherapeutics
Our BDC-3042 product candidate reawakens myeloid cells to attack tumor cells. We discovered an agonist monoclonal antibody that is capable of binding to and activating a pattern …See details»